Guidelines to PET Measurements of the Target Occupancy in the Brain for Drug Development

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2016 Aug 13

PMID 27514528

Citations 19

Authors

Akihiro Takano

Andrea Varrone

Balazs Gulyas

Piero Salvadori

Antony Gee

Albert Windhorst

Johnny Vercouillie

Guy Bormans

Adriaan A Lammertsma

Christer Halldin

Affiliations

Soon will be listed here.

Abstract

This guideline summarizes the current view of the European Association of Nuclear Medicine Drug Development Committee. The purpose of this guideline is to guarantee a high standard of PET studies that are aimed at measuring target occupancy in the brain within the framework of development programs of drugs that act within the central nervous system (CNS drugs). This guideline is intended to present information specifically adapted to European practice. The information provided should be applied within the context of local conditions and regulations.

Citing Articles

Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.

Terry-Lorenzo R, Albrecht D, Crouch S, Wong R, Loewen G, Giri N Neuropsychopharmacology. 2025; .

PMID: 39757283 DOI: 10.1038/s41386-024-02046-3.

Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development.

Ahmed H, Wang Y, Griffiths W, Levey A, Pikuleva I, Liang S Brain. 2024; 147(5):1622-1635.

PMID: 38301270 PMC: 11068113. DOI: 10.1093/brain/awae028.

SLIC-Occ: functional segmentation of occupancy images improves precision of EC images.

Ibrahimy A, Hoye J, Wu H, de Laat B, Kim S, Wilson D EJNMMI Phys. 2023; 10(1):80.

PMID: 38079001 PMC: 10713928. DOI: 10.1186/s40658-023-00600-4.

Preliminary Exploration of Pseudo-CT-Based Attenuation Correction for Simultaneous PET/MRI Brain Imaging in Nonhuman Primates.

Yoo C, DuBois J, Wang L, Tang Y, Hou L, Xu H ACS Omega. 2023; 8(48):45438-45446.

PMID: 38075761 PMC: 10702200. DOI: 10.1021/acsomega.3c04824.

Kinetic models for estimating occupancy from single-scan PET displacement studies.

Laurell G, Plaven-Sigray P, Johansen A, Raval N, Nasser A, Aabye Madsen C J Cereb Blood Flow Metab. 2023; 43(9):1544-1556.

PMID: 37070382 PMC: 10414003. DOI: 10.1177/0271678X231168591.

References

Zanotti-Fregonara P, Innis R . Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2011; 39(3):544-7. PMC: 3791506. DOI: 10.1007/s00259-011-2005-8. View

Ichise M, Liow J, Lu J, Takano A, Model K, Toyama H . Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003; 23(9):1096-112. DOI: 10.1097/01.WCB.0000085441.37552.CA. View

Logan J, Fowler J, Volkow N, Wang G, Ding Y, Alexoff D . Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996; 16(5):834-40. DOI: 10.1097/00004647-199609000-00008. View

Lassen N, Bartenstein P, Lammertsma A, Prevett M, Turton D, Luthra S . Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab. 1995; 15(1):152-65. DOI: 10.1038/jcbfm.1995.17. View

ICRP . Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2009; 38(1-2):1-197. DOI: 10.1016/j.icrp.2008.08.003. View

Lee C, Farde L . Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci. 2006; 27(6):310-6. DOI: 10.1016/j.tips.2006.04.004. View

DiMasi J, Hansen R, Grabowski H . The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22(2):151-85. DOI: 10.1016/S0167-6296(02)00126-1. View

Bench C, Lammertsma A, Grasby P, Dolan R, Warrington S, Boyce M . The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology (Berl). 1996; 124(1-2):141-7. DOI: 10.1007/BF02245614. View

Lammertsma A, Hume S . Simplified reference tissue model for PET receptor studies. Neuroimage. 1996; 4(3 Pt 1):153-8. DOI: 10.1006/nimg.1996.0066. View

10.

Innis R, Cunningham V, Delforge J, Fujita M, Gjedde A, Gunn R . Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27(9):1533-9. DOI: 10.1038/sj.jcbfm.9600493. View

11.

Halldin C, Gulyas B, Farde L . PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des. 2002; 7(18):1907-29. DOI: 10.2174/1381612013396871. View

12.

. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007; 37(2-4):1-332. DOI: 10.1016/j.icrp.2007.10.003. View

13.

Bench C, Price G, Lammertsma A, Cremer J, Luthra S, Turton D . Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol. 1991; 40(2):169-73. DOI: 10.1007/BF00280072. View

14.

Fowler J, Wang G, Logan J, Xie S, Volkow N, MacGregor R . Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med. 1995; 36(7):1255-62. View

15.

Meyer J, Wilson A, Sagrati S, Hussey D, Carella A, Potter W . Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004; 161(5):826-35. DOI: 10.1176/appi.ajp.161.5.826. View

16.

Terry G, Liow J, Zoghbi S, Hirvonen J, Farris A, Lerner A . Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage. 2009; 48(2):362-70. PMC: 2730982. DOI: 10.1016/j.neuroimage.2009.06.059. View

17.

Farde L, Nordstrom A, Wiesel F, Pauli S, Halldin C, Sedvall G . Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49(7):538-44. DOI: 10.1001/archpsyc.1992.01820070032005. View

18.

Zanotti-Fregonara P, Lammertsma A, Innis R . Suggested pathway to assess radiation safety of ¹⁸F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2013; 40(11):1781-3. PMC: 3844925. DOI: 10.1007/s00259-013-2512-x. View

19.

Bench C, Lammertsma A, Dolan R, Grasby P, Warrington S, Gunn K . Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride. Psychopharmacology (Berl). 1993; 112(2-3):308-14. DOI: 10.1007/BF02244926. View

20.

Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y . A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl). 2006; 185(3):395-9. DOI: 10.1007/s00213-005-0304-0. View